Order number AK1604-S 100 assays
The AKCELL KRAS AK™PCR Mutation Screen Kit is designed to screen for mutations on
the KRAS gene in genomic DNA, commonly associated with colorectal cancer patients.
KRAS Mutations and Cancer
KRAS (pronounced “k-ras”) also known as V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog, is a GTPase that in humans is encoded by the KRAS gene.
The protein product of the normal KRAS gene performs an essential function in normal tissue signaling, and the mutation of a KRAS gene is an essential step in the development of many cancers.
KRAS mutations have been commonly found in several types of human malignancies, such as metastatic colorectal cancer (mCRC), lung adenocarcinoma and thyroid cancer. The most common mutations are found in codons 12, 13 and 61.
The American Society of Clinical Oncology (ASCO) recommends that before treatment with anti–EGFR antibody therapy, patients with mCRC should have their tumor tested for mutations in: KRAS exons 3 (codons 59 and 61) and KRAS exons 4 (codons 117 and 146) in addition to the previously recommended testing of KRAS exon 2 (codons 12 and 13).
Compatible with ABI 7500 Real-Time Systems or equivalent.
AKCELL’s KRAS mutation screen reagents are provided for research use only (RUO).
1. McGrath JP, Capon DJ, Smith DH, Chen EY, Seeburg PH, Goeddel DV, Levinson AD (1983). “Structure and organization of the human Ki-ras proto-oncogene and a related processed pseudogene”. Nature 304 (5926): 501–6.
2. Popescu NC, Amsbaugh SC, DiPaolo JA, Tronick SR, Aaronson SA, Swan DC (Mar 1985). “Chromosomal localization of three human ras genes by in situ molecular hybridization”. Somatic Cell and Molecular Genetics 11 (2): 149–55.
3. Kranenburg O (Nov 2005). “The KRAS oncogene: past, present, and future”.Biochimica et Biophysica Acta 1756 (2): 81–2.